Cellective BioTherapy
Raleigh
About Cellective BioTherapy
Cellective BioTherapy develops novel cellular and monoclonal antibody-based platforms to treat cancer, autoimmunity, and immunodeficiency. The biotechnology company focuses on the research and development of B cell-based cellular therapies for immunomodulation, immunodeficiency, and autoimmunity. It researches treatment for cancers, diabetes, asthma, and congenital and acquired immunodeficiency, and vaccine development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.5M
- Funding stage: Seed
- Last round: Angel (Jun 2015)
- Website: cellectivebiotherapy.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Information Technology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/cellective-biotherapy-2729719 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.